Top Nasdaq Stocks is issuing a report on three stocks to watch. New York & Company, Inc. (NYSE:NWY), Oncothyreon Inc (USA) (NASDAQ:ONTY), and Transgenomic Inc (NASDAQ:TBIO) have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
New York & Company, Inc. (NYSE:NWY) is a professional clothing retailer for women. The attire is distributed through a countrywide network of retail shops, New York & Company Outlet Stores and through its website. NWY released its Q4 2015 results this week. As of the 17th, the stock price has climbed 32% in the month of March, with a maximum daily return of 18.5% on March 1st. In addition, during the first trading week of March, the stock’s price rose at a 15% clip, and climbed 9.05% in the following week.
Stay Informed and Up To Date On The Hottest NASDAQ Plays Like NWY Before They Break Out. Get Them Here.
Oncothyreon Inc (USA) (NASDAQ:ONTY) has had its stock price rise at a rate of 19.94% since the month of March began. During that same time period, the stock reached highs of $1.275 and delivered a daily return of 8.41%. Oncothyreon, Inc. is a biotechnology company focused on developing oncology products that can better the lives and results of cancer patients. The company is devoted to creating cancer treatments that minimizes damage to the cancer’s surrounding healthy tissue.
Members of record by 4PM March 18 will secure a place-holder to receive our next report. Get Your Free Membership Now.
Transgenomic Inc (NASDAQ:TBIO) is a biotechnology company furthering tailored medicine in oncology, cardiology, neurology, and genetic conditions through advanced diagnostic technologies, products and services. Since March 1st, the stock has increased 23.21% with return potential of 12.70% on March 7th. Furthermore, the stock’s volume has ascended 49.64% from 17,969 shares to 26,889 shares thus far during the month.
Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word “NASDAQ” to 77948
Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don’t forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text “NASDAQ” to 77948.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.
Top Nasdaq Stocks
SOURCE: Top Nasdaq Stocks
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.